ELEVATE: an innovative study design to assess the efficacy, safety, and evolution of cardiovascular parameters in de novo kidney transplant recipients after early conversion from a calcineurin inhibitor to everolimus
Markus van der Giet,1 Josep M Cruzado,2 Johan W de Fijter,3 Hallvard Holdaas,4 Zailong Wang,5 Antonio Speziale,6 Guido Junge61Department of Nephrology, Campus Benjamin Franklin, Charite'-Universitätsmedizin, Berlin, Germany; 2Department of Nephrology, University Hospital of Bellvitg...
Main Authors: | van der Giet M, Cruzado JM, de Fijter JW, Holdaas H, Wang Z, Speziale A, Junge G |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2014-03-01
|
Series: | Open Access Journal of Clinical Trials |
Online Access: | http://www.dovepress.com/elevate-an-innovative-study-design-to-assess-the-efficacy-safety-and-e-a16196 |
Similar Items
-
Treatment of De Novo Renal Transplant Recipients With Calcineurin Inhibitor–free, Belatacept Plus Everolimus–based Immunosuppression
by: V. Ram Peddi, MD, et al.
Published: (2023-02-01) -
Analysis of early use of everolimus with low-dose calcineurin inhibitors in kidney transplant recipient
by: I. G. Kim, et al.
Published: (2019-10-01) -
EVEROLIMUS IN DE NOVO RENAL TRANSPLANT RECIPIENTS
by: E. I. Prokopenko
Published: (2010-06-01) -
Early calcineurin-inhibitor to belatacept conversion in steroid-free kidney transplant recipients
by: Ibrahim Tawhari, et al.
Published: (2022-12-01) -
Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical TrialPlain-Language Summary
by: Obbo W. Bredewold, MD, et al.
Published: (2023-01-01)